Aurigene and Vipergen Enter into a Strategic Collaboration to Offer DEL Screening and Integrated Drug Discovery Services
Shots:
- This collaboration will combine Vipergen's high-fidelity DEL screening technologies and Aurigene Pharmaceutical Services' existing small molecule drug discovery capabilities to enhance end-to-end discovery solutions with advanced hit screening
- Companies will co-market and introduce DEL screening technologies to global customers as an integrated drug discovery service or a standalone service
- With a focus on novel chemical diversity and drug likeliness, companies will also co-develop new DELs to strengthen their services
Ref: Aurigene | Image: Aurigene
Related News:- Dr. Reddy's Subsidiary Aurigene Stops Clinical Development of AUR-101 for the Treatment of Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
